Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer
Stopped early · Phase 1
Conditions studied: Cancer
In brief
Phase 1 Open-label treatment with MPC-2130 for subjects with refractory cancer.
Key facts
- Study ID
- NCT00387153
- Run by
- Myriad Therapeutics, Inc.
- People needed
- 8
- Starts
- 2005-08-01
- Expected to finish
- 2006-10-01
- Last updated by the study team
- 2009-11-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Be capable of understanding the informed consent form (ICF) and complying with the protocol, and must sign the ICF prior to the performance of any study related procedures;
- Have cancer that is nonresponsive despite prior treatment with current standard of care regimens or for whom there are no available effective therapies;
- Have measurable or evaluable neoplastic disease;
- Be greater than or equal to age 18;
- Have and ECOG Performance Status score of less than or equal to 2;
- Have adequate organ function defined by:
- Liver function tests (AST \& ALT) less than or equal to 3 times the upper limit of normal (ULN);
- Bilirubin less than or equal to 1.5 X ULN;
- Serum Creatinine less than or equal to 1.5 X ULN;
- Hemoglobin greater than or equal to 8.0 g/dL;
- Have recovered or stabilized from clinically significant toxicities of prior chemotherapy, surgery, or radiotherapy;
- Have left ventricular ejection fraction (LVEF) of greater than or equal to 45% by multiple gated acquisition (MUGA) scan or echocardiogram.
You may not qualify if…
- Have had a prior serious, uncontrollable hypersensitivity reaction to Cremophor EL;
- Be pregnant or lactating (women of childbearing potential must use appropriate birth control (abstinence, barrier methods, oral contraceptives and/or intrauterine devices) during the entire duration of the study, or the patient must be surgically sterile (with documentation in the patient's medical records);
- Receive any other anticancer treatment or investigational therapy within 14 days prior to day 1; or within 6 weeks after prior mitomycin C or nitrosourea. Patients with advanced prostate cancer may continue to receive leutinizing hormone-releasing hormone (LHRH) therapy while in this study;
- Have previously enrolled in this trial. -
Where it is running
- MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.